391 related articles for article (PubMed ID: 26689746)
1. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
Loschi M; Porcher R; Barraco F; Terriou L; Mohty M; de Guibert S; Mahe B; Lemal R; Dumas PY; Etienne G; Jardin F; Royer B; Bordessoule D; Rohrlich PS; Fornecker LM; Salanoubat C; Maury S; Cahn JY; Vincent L; Sene T; Rigaudeau S; Nguyen S; Lepretre AC; Mary JY; Corront B; Socie G; Peffault de Latour R
Am J Hematol; 2016 Jun; 91(4):366-70. PubMed ID: 26689746
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
[TBL] [Abstract][Full Text] [Related]
4. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
6. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
Sicre de Fontbrune F; Peffault de Latour R
Semin Hematol; 2018 Jul; 55(3):124-129. PubMed ID: 30032748
[TBL] [Abstract][Full Text] [Related]
7. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go?
Alashkar F; Dührsen U; Röth A
Eur J Haematol; 2016 Oct; 97(4):403-5. PubMed ID: 26990688
[TBL] [Abstract][Full Text] [Related]
8. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.
Bauters T; Bordon V; Robays H; Benoit Y; Dhooge C
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e346-8. PubMed ID: 22767128
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
[TBL] [Abstract][Full Text] [Related]
10. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
Hill A; Richards SJ; Rother RP; Hillmen P
Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
[TBL] [Abstract][Full Text] [Related]
11. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
12. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
13. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
15. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.
Jang JH; Kim JS; Yoon SS; Lee JH; Kim YK; Jo DY; Chung J; Sohn SK; Lee JW
J Korean Med Sci; 2016 Feb; 31(2):214-21. PubMed ID: 26839475
[TBL] [Abstract][Full Text] [Related]
16. [Clinical progress of paroxysmal nocturnal hemoglobinuria].
Gong YW; He GS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1627-30. PubMed ID: 24370061
[TBL] [Abstract][Full Text] [Related]
17. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.
van Bijnen ST; Østerud B; Barteling W; Verbeek-Knobbe K; Willemsen M; van Heerde WL; Muus P
Thromb Res; 2015 Aug; 136(2):274-81. PubMed ID: 26143713
[TBL] [Abstract][Full Text] [Related]
18. [Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab].
Tsutsui M; Gotoh A; Yasuda H; Ono E; Tanaka M; Komatsu N
Rinsho Ketsueki; 2015 Apr; 56(4):423-7. PubMed ID: 25971274
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Füreder W; Sperr WR; Heibl S; Zebisch A; Pfeilstöcker M; Stefanzl G; Jäger E; Greiner G; Schwarzinger I; Kundi M; Keil F; Hoermann G; Bettelheim P; Valent P
Ann Hematol; 2020 Oct; 99(10):2303-2313. PubMed ID: 32856141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]